SAN FRANCISCO, March 31, 2021 /PRNewswire/ -- Audentes Therapeutics, an Astellas Company, today announced that it is expanding its mission to deve ...

Sanford is where Astellas Gene Therapies last year opened a $100-million late-stage clinical and commercial manufacturing facility, the company’s third devoted to producing gene therapies.

Shares of Taysha Gene Therapies (NASDAQ:TSHA) have fallen by 85% since the September 2020 IPO was priced at $20.Performance is an even more brutal -88% since my initial article was published in ...

Astellas has gene therapy candidates spanning various stages of development. ... paying $50 million for an equity stake in the biotech and the option to license two CNS gene therapies, ...

A Q&A with Naoki Okamura revealed that when it comes to cell and gene therapies, the CEO of Astellas Pharma believes risk-taking is a must for eventual success. By Arundhati Parmar on May 10, 2024 ...

Astellas Gene Therapies signaled plans to further expand in its namesake focus area when it joined Taysha Gene Therapies (TSHA) this week to announce a $50 million investment in the Dallas drug ...

About Astellas Gene Therapies Astellas integrated its wholly owned subsidiary, Audentes Therapeutics, Inc. as of April 1, 2021 and established "Astellas Gene Therapies" within the organization ...

Gene Therapies Center of Excellence focuses on AAV. The new operation is part of the Astellas Gene Therapies Center of Excellence that was created following the 2020 acquisition of San Francisco ...

Kenji Yasukawa, Ph.D., the new Astellas CEO, pledged to push the Japanese drugmaker further into gene and cell therapies for ocular, oncology and other diseases. Now the company says it will ...

Astellas’ gene therapy strategy is sinking deeper into the mire. ... (DMD) gene therapies, the Japanese drugmaker has decided to scrap the candidates, triggering a $170 million impairment loss.

Global pharmaceutical firm Astellas, which operates a $100 million gene therapy manufacturing plant in Sanford, is investing $50 million in San Diego-based Poseida Therapeutics.

Gene therapies that replace a single missing or faulty gene have been successful in treating some disorders, ... Astellas is working on a gene therapy that expresses two proteins, ...